casirivimab, imdevimab - søkeresultat

Den europeiske union - norsk - EMA (European Medicines Agency)

ronapreve

roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se avsnitt 4. 4 og 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

simulect

novartis europharm limited - basiliximab - graft rejection; kidney transplantation - immunsuppressive - simulect er indisert for profylakse av akutt organavstødning i de-novo allogen nyretransplantasjon hos voksne og pediatriske pasienter (1-17 år). det er til å bli brukt samtidig med ciclosporin for microemulsion - og kortikosteroid-basert immunsuppresjon hos pasienter med panel reaktiv antistoffer mindre enn 80%, eller i en trippel vedlikehold immunsuppressiv diett som inneholder ciclosporin for microemulsion, kortikosteroider og enten azatioprin eller mycophenolate mofetil.

Den europeiske union - norsk - EMA (European Medicines Agency)

vabysmo

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - Øyemidler - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Den europeiske union - norsk - EMA (European Medicines Agency)

idefirix

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunsuppressive - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Den europeiske union - norsk - EMA (European Medicines Agency)

nulojix

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunsuppressive - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.